3 Pieces of Research

This double-blind, placebo-controlled study (n=24) evaluated the metabolism and clinical pharmacokinetics (how the body processes drugs) of DMT (SPL026) in an ongoing Phase I study with healthy subjects by Small Pharma. Participants received escalating doses of SPL026 via a 2-phase intravenous (IV) infusion. SP206 was safe and well-tolerated, and dose-proportional increases in DMT exposure were observed over 9–21.5 mg. For all doses, the median time to peak plasma concentration was ~10 min, and the mean elimination half-life was 9–12 min.

This pre-print analysis of online (Reddit) posts finds that classical psychedelics benefited 75% of those who mentioned the effects (10% negative). The benefits spanned behavioural change (e.g. reduced stuttering), emotional benefit, and cognitive changes.

This survey (n=2045) of Canadian psychedelic users finds psilocybin, MDMA and LSD are the most commonly used. It also reports positive (82%) life changes and challenging experiences (52%). Motivations for use include fun, self-exploration, general mental well-being, and personal growth.

2 Parts News

MAPS has shared that their (part 1 of 2) Phase III FDA study is a success. This means that there is a significant difference in PTSD measures in the double-blind placebo-controlled 90 person study.

Beckley Psytech raised $18.6 million to continue their work with 5-MeO-DMT. It will be interesting to (in a few years) see how they will develop, especially as Usona last week made the process for making 5-MeO-DMT at scale public.

1 Psychedelic Song

M83 – Wait sets you up for a moment of reflection and awe. With limited lyrics, the song is open to various interpretations.